We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00457457
Recruitment Status : Completed
First Posted : April 6, 2007
Last Update Posted : November 1, 2010
Information provided by:

Brief Summary:
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaires before, during and after treatment to assess if UK-369,003 has improved their urinary symptoms and erectile function . There will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.

Condition or disease Intervention/treatment Phase
Prostatic Hyperplasia Drug: Tamsulosin Drug: UK-369,003 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 609 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)
Study Start Date : May 2007
Primary Completion Date : April 2008
Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Comparator
Tamsulosin 0.4 mg prolonged release
Drug: Tamsulosin
Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
Experimental: Treatment Arm
There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
Drug: UK-369,003
UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED

Primary Outcome Measures :
  1. Change in international prostate symptom score [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Erectile Function (EF) domain of International Index of Erectile [ Time Frame: 12 weeks ]
  2. Function (IIEF) [ Time Frame: 12 weeks ]
  3. Qmax [ Time Frame: 12 weeks ]
  4. Quality of Erection questionnaire (QEQ) [ Time Frame: 12 weeks ]
  5. Population pharmacokinetics [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male subjects aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13
  2. Clinical diagnosis of BPH.
  3. Qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening).

Exclusion Criteria:

  1. Urinary tract infection
  2. Primary neurological conditions affecting bladder function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00457457

  Hide Study Locations
Australia, Queensland
Pfizer Investigational Site
Herston, Queensland, Australia
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
Pfizer Investigational Site
Brussels, 1200, Belgium
Pfizer Investigational Site
Brussels, Belgium, B-1090
Pfizer Investigational Site
Edegem, Belgium, B-2650
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T2V 4R6
Canada, Ontario
Pfizer Investigational Site
London, Ontario, Canada, N6A 4V2
Canada, Quebec
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada, H9R 4S3
Pfizer Investigational Site
Temuco, IX Region, Chile, 4810371
Pfizer Investigational Site
Santiago, Chile
Pfizer Investigational Site
Medellin, Antioquia, Colombia, 0
Pfizer Investigational Site
Barranquilla, Atlantico, Colombia, 0
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia, 0
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca, Colombia, 0
Pfizer Investigational Site
Aalborg, Denmark, 9100
Pfizer Investigational Site
Aarhus N, Denmark, 8200
Pfizer Investigational Site
Gentofte, Denmark, 2820
Pfizer Investigational Site
Helsinki, Finland, 00100
Pfizer Investigational Site
Kuopio, Finland, 70100
Pfizer Investigational Site
Oulu, Finland, 90100
Pfizer Investigational Site
Tampere, Finland, 33100
Pfizer Investigational Site
Larissa, Greece, 41110
Pfizer Investigational Site
Rio, Greece, 26500
Pfizer Investigational Site
Thessaloniki, Greece, 56403
Pfizer Investigational Site
Foggia, Italy, 71100
Pfizer Investigational Site
Siena, Italy, 53100
Pfizer Investigational Site
Riga, Latvia, LV-1002
Pfizer Investigational Site
Kaunas, Lithuania, 47144
Pfizer Investigational Site
Kaunas, Lithuania, 50009
Pfizer Investigational Site
Vilnius, Lithuania, 08661
Pfizer Investigational Site
Bydgoszcz, Poland, 85-092
Pfizer Investigational Site
Bydgoszcz, Poland, 85-168
Pfizer Investigational Site
Gdansk, Poland, 80-402
Pfizer Investigational Site
Gdynia, Poland, 81-393
Pfizer Investigational Site
Myslowice, Poland, 41-400
Pfizer Investigational Site
Wejherowo, Poland, 84-200
Pfizer Investigational Site
Bratislava, Slovakia, 851 01
Pfizer Investigational Site
Malacky, Slovakia, 901 01
Pfizer Investigational Site
Nitra, Slovakia, 949 01
Pfizer Investigational Site
Prešov, Slovakia, 080 01
Pfizer Investigational Site
Skalica, Slovakia, 909 82
Pfizer Investigational Site
Madrid, Spain, 28035
Pfizer Investigational Site
Malaga, Spain, 29010
Pfizer Investigational Site
Valencia, Spain, 46010
United Kingdom
Pfizer Investigational Site
Bristol, United Kingdom, BS2 8HW
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00457457     History of Changes
Other Study ID Numbers: A3711044
First Posted: April 6, 2007    Key Record Dates
Last Update Posted: November 1, 2010
Last Verified: October 2010

Keywords provided by Pfizer:
With or without erectile dysfunction

Additional relevant MeSH terms:
Erectile Dysfunction
Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Pathologic Processes
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Prostatic Diseases
Urological Manifestations
Signs and Symptoms
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents